Overexpression of HER2 neu as a prognostic value in Iranian women with early stage breast cancer : a single institute study
Joint Authors
Mahyari, Hanifah Mirtavoos
Khosravi, Adnan
Mahyari, Zaynab Mirtavoos
Monfared, Zahra Esfahani
Khosravi, Negin
Source
Iranian Red Crescent Medical Journal
Issue
Vol. 16, Issue 11 (30 Nov. 2014), pp.1-8, 8 p.
Publisher
Publication Date
2014-11-30
Country of Publication
United Arab Emirates
No. of Pages
8
Main Subjects
Topics
Abstract EN
Background : Patients with early stage breast cancer with same treatment strategy can have markedly different outcomes.
Human epidermal growth factor receptor 2 (HER2 / nue) gene amplification or the subsequent overexpression of protein has been proved to be associated with patient's outcome and response to anthracyclins-based regimens.
Objectives : This study assessed prognostic value of HER2 / nue marker in patients with early stage breast cancer who received adjuvant chemotherapy with anthracyclins-based regimens.
Materials and Methods : Fifty tissue samples from patients with primary breast cancer of moderate risk receiving sequential adjuvant chemotherapy with anthracyclins-based regimens were assessed to evaluate HER2 / nue gene status (quantified by Immunohistochemistry and fluorescence in situ hybridization) retrospectively.
Besides, correlation of HER2 / neu with patients' characteristics and outcome was studied.
Results : HER2 / neu amplification was identified in 19 (38 %) of 50 patients.
No significant difference regarding HER2 / neu status was seen in clinic pathological characteristics of patients.
Although Progression Free Survival (PFS) was shorter in HER2 overexpressed group, but uni / multivariate analysis adjusted for HER2 overexpression, nodal involvement, hormone receptor status, age and tumor size revealed no significant predictive and / or prognostic value for HER2 regarding PFS.
Conclusions : This study on a limited number of patients treated with adjutant anthracyclins-based regimens, revealed that HER2 / neu is not a unique strong predictor for outcome, thus according to combination of HER2 / neu status and other clinical factors, it is necessary to distinguish patients at high risk of recurrence.
American Psychological Association (APA)
Mahyari, Hanifah Mirtavoos& Khosravi, Adnan& Mahyari, Zaynab Mirtavoos& Monfared, Zahra Esfahani& Khosravi, Negin. 2014. Overexpression of HER2 neu as a prognostic value in Iranian women with early stage breast cancer : a single institute study. Iranian Red Crescent Medical Journal،Vol. 16, no. 11, pp.1-8.
https://search.emarefa.net/detail/BIM-428212
Modern Language Association (MLA)
Mahyari, Hanifah Mirtavoos…[et al.]. Overexpression of HER2 neu as a prognostic value in Iranian women with early stage breast cancer : a single institute study. Iranian Red Crescent Medical Journal Vol. 16, no. 11 (Nov. 2014), pp.1-8.
https://search.emarefa.net/detail/BIM-428212
American Medical Association (AMA)
Mahyari, Hanifah Mirtavoos& Khosravi, Adnan& Mahyari, Zaynab Mirtavoos& Monfared, Zahra Esfahani& Khosravi, Negin. Overexpression of HER2 neu as a prognostic value in Iranian women with early stage breast cancer : a single institute study. Iranian Red Crescent Medical Journal. 2014. Vol. 16, no. 11, pp.1-8.
https://search.emarefa.net/detail/BIM-428212
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 7-8
Record ID
BIM-428212